首页> 外文OA文献 >Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials
【2h】

Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials

机译:儿童和青少年精神分裂症频谱疾病的抗精神病药物治疗:随机试验网络荟萃分析的方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Introduction: Antipsychotic treatment in early-onset schizophrenia (EOS) lacks a rich evidence base, and efforts to rank different drugs concerning their efficacy have not proven any particular drug superior. In contrast to the literature regarding adult-onset schizophrenia (AOS), comparative effectiveness studies in children and adolescents are limited in number and size, and only a few meta-analyses based on conventional methodologies have been conducted. Methods and analyses: We will conduct a network meta-analysis of all randomised controlled trials (RCTs) that evaluate antipsychotic therapies for EOS to determine which compounds are efficacious, and to determine the relative efficacy and safety of these treatments when compared in a network meta-analysis. Unlike a contrast-based (standard) meta-analysis approach, an arm-based network meta-analysis enables statistical inference from combining both direct and indirect comparisons within an empirical Bayes framework. We will acquire eligible studies through a systematic search of MEDLINE, the Cochrane Central Registry of Controlled Trials, Clinicaltrials.gov and Centre for Reviews and Dissemination databases. Eligible studies should randomly allocate children and adolescents presenting with schizophrenia or a related non-affective psychotic condition to an intervention group or to a control group. Two reviewers will-independently and in duplicate-screen titles and abstracts, complete full text reviews to determine eligibility, and subsequently perform data abstraction and assess risk of bias of eligible trials. We will conduct meta-analyses to establish the effect of all reported therapies on patient-relevant efficacy and safety outcomes when possible. Ethics and dissemination: No formal ethical procedures regarding informed consent are required as no primary data collection is undertaken. The review will help facilitate evidence-based management, identify key areas for future research, and provide a framework for conducting large systematic reviews combining direct and indirect comparisons. The study will be disseminated by peer-reviewed publication and conference presentation.
机译:简介:早发性精神分裂症(EOS)的抗精神病药物治疗缺乏丰富的证据基础,并且就其功效对不同药物进行分级的努力尚未证明有任何特定的药物优越性。与有关成人发作性精神分裂症(AOS)的文献相反,在儿童和青少年中进行的比较有效性研究的数量和规模均受到限制,并且仅进行了一些基于常规方法的荟萃分析。方法和分析:我们将对所有随机对照试验(RCT)进行网络荟萃分析,以评估EOS的抗精神病药物疗法,以确定哪些化合物有效,并确定与网络荟萃相比这些疗法的相对疗效和安全性-分析。与基于对比的(标准)荟萃分析方法不同,基于手臂的网络荟萃分析可通过结合经验贝叶斯框架内的直接和间接比较来进行统计推断。我们将通过系统搜索MEDLINE,Cochrane对照试验中央注册中心,Clinicaltrials.gov和评论与传播中心数据库来获得合格的研究。符合条件的研究应将患有精神分裂症或相关的非情感性精神病的儿童和青少年随机分配到干预组或对照组。两名审阅者将独立进行重复屏幕标题和摘要的审阅,完成全文审阅以确定资格,然后进行数据摘要并评估符合条件的试验存在偏倚的风险。如果可能,我们将进行荟萃分析,以建立所有报告疗法对患者相关疗效和安全性结果的影响。道德与传播:由于无需进行主要数据收集,因此不需要有关知情同意的正式道德程序。审查将有助于促进基于证据的管理,确定未来研究的关键领域,并为进行直接和间接比较相结合的大型系统审查提供框架。这项研究将通过同行评审的出版物和会议介绍进行传播。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号